INSMED Inc. Files 8-K Report

Ticker: INSM · Form: 8-K · Filed: 2025-06-10T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, regulation-fd

TL;DR

INSMED filed an 8-K, likely with updates. Keep an eye out for details.

AI Summary

On June 10, 2025, INSMED Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial statements and exhibits. No specific material events or financial figures beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates INSMED Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific operational or financial news that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by INSMED Inc.?

The 8-K filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of June 10, 2025.

What is INSMED Inc.'s state of incorporation and IRS Employer Identification Number?

INSMED Inc. is incorporated in Virginia and its IRS Employer Identification Number is 54-1972729.

Where are INSMED Inc.'s principal executive offices located?

INSMED Inc.'s principal executive offices are located at 700 US Highway 202/206, Bridgewater, New Jersey 08807.

What is the Commission File Number for INSMED Inc.?

The Commission File Number for INSMED Inc. is 000-30739.

On what date was this 8-K report filed or effective?

The report was filed as of June 10, 2025, and the date of the earliest event reported is also June 10, 2025.

From the Filing

0001140361-25-022023.txt : 20250610 0001140361-25-022023.hdr.sgml : 20250610 20250610070027 ACCESSION NUMBER: 0001140361-25-022023 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20250610 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 251035919 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 ef20050418_8k.htm 8-K false 0001104506 0001104506 2025-06-10 2025-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia   000-30739   54-1972729 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 700 US Highway 202/206 Bridgewater , New Jersey   08807 (Zip Code) (Address of principal executive offices)     Registrant’s telephone number, including area code: ( 908 ) 977-9900 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ITEM 7.01 — Regulation FD Disclosure. On June 10, 2025, Insmed Incorporated (the “Company”) issued a press release announcing positive topline results from its Phase 2b study of treprostinil palmitil inhalation powder (“TPIP”) in patients with pulmonary arterial hypertension (“PAH”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company will host a conference call to discuss the positive topline results of the TPIP PAH study on June 10, 2025, at 8:00 a.m., Eastern Time, and a live webcast of the call will be available through the investor relations section of the Company’s website. A copy of the slide presentation to be used by the Company during the conference

View on Read The Filing